| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
HCM
HUTCHMED
|
Oct 27, 2026 | BUY |
Strong Buy
+135.4% avg upside
9 analysts
|
$18.00
36.97% Upside
|
+7.6% | Β· |
|
ERAS
Erasca
|
Oct 27, 2026 | HOLD |
Strong Buy
+46.3% avg upside
14 analysts
|
$20.00
39.37% Upside
|
-0.7% | Β· |
|
BEAM
Beam Therapeutics
|
Oct 27, 2026 | BUY |
Strong Buy
+91.1% avg upside
25 analysts
|
$43.00
57.97% Upside
|
-8.3% | Β· |
|
MRNA
Moderna
|
Oct 27, 2026 | HOLD |
Hold
-48.5% avg upside
38 analysts
|
$220.00
0.86% Downside
|
+7.4% | Β· |
|
CATX
Perspective Therapeutics
|
Oct 26, 2026 | HOLD |
Strong Buy
+759.2% avg upside
24 analysts
|
$5.00
334.69% Upside
|
-22.3% | Β· |
|
IMTX
Immatics
|
Oct 26, 2026 | BUY |
Strong Buy
+144.6% avg upside
16 analysts
|
$17.00
136.09% Upside
|
-13.7% | Β· |
|
RVMD
Revolution Medicines
|
Oct 26, 2026 | BUY |
Strong Buy
+8.2% avg upside
36 analysts
|
$264.00
37.99% Upside
|
-6.3% | Β· |
|
XNCR
Xencor
|
Oct 26, 2026 | HOLD |
Strong Buy
+31.7% avg upside
29 analysts
|
$26.00
12.75% Downside
|
+35.0% | Β· |
|
NVAX
Novavax
|
Oct 23, 2026 | SELL |
Hold
+130.2% avg upside
20 analysts
|
$8.00
20.54% Downside
|
+16.9% | Β· |
|
RGNX
RegenXBio
|
Oct 21, 2026 | BUY |
Strong Buy
+389.7% avg upside
25 analysts
|
$15.00
108.27% Upside
|
+2.1% | Β· |
|
RXRX
Recursion Pharmaceuticals
|
Oct 16, 2026 | HOLD |
Buy
+92.8% avg upside
12 analysts
|
$6.00
48.93% Upside
|
-16.2% | Β· |
|
ALEC
Alector
|
Oct 14, 2026 | SELL |
Buy
+370.1% avg upside
15 analysts
|
$1.00
54.75% Downside
|
-35.1% | Β· |
|
CRSP
Crispr Therapeutics AG
|
Oct 09, 2026 | BUY |
Buy
+45.6% avg upside
41 analysts
|
$81.00
57.51% Upside
|
-20.9% | Β· |
|
AGIO
Agios Pharma
|
Oct 06, 2026 | BUY |
Strong Buy
+98.9% avg upside
30 analysts
|
$50.00
63.68% Upside
|
+1.0% | Β· |
|
WVE
Wave Life Sciences
|
Oct 01, 2026 | BUY |
Strong Buy
+443.6% avg upside
30 analysts
|
$17.00
373.46% Upside
|
-19.3% | Β· |
|
PRQR
ProQR
|
Sep 30, 2026 | BUY |
Strong Buy
+683.4% avg upside
19 analysts
|
$8.00
475.49% Upside
|
-15.1% | Β· |
|
CADL
Candel Therapeutics
|
Sep 30, 2026 | BUY |
Strong Buy
+134.0% avg upside
12 analysts
|
$18.00
116.15% Upside
|
-39.2% | Β· |
|
KRYS
Krystal Biotech
|
Sep 21, 2026 | BUY |
Strong Buy
-15.3% avg upside
20 analysts
|
$400.00
20.33% Upside
|
-8.6% | Β· |
|
MGTX
Meiragtx Holdings
|
Aug 14, 2026 | BUY |
Strong Buy
+166.7% avg upside
14 analysts
|
$19.00
100.14% Upside
|
-35.4% | Β· |
|
AKTS
Aktis Oncology, Inc.
|
Aug 14, 2026 | BUY |
Strong Buy
+104.0% avg upside
12 analysts
|
$34.00
113.36% Upside
|
-35.9% | Β· |
|
CRBU
Caribou Biosciences
|
Aug 14, 2026 | BUY |
Strong Buy
+1510.4% avg upside
13 analysts
|
$5.00
1081.47% Upside
|
-77.7% | Β· |
|
SANA
Sana Biotechnology
|
Aug 14, 2026 | BUY |
Strong Buy
+282.6% avg upside
14 analysts
|
$6.00
133.54% Upside
|
-43.1% | Β· |
|
VIR
Vir Biotechnology
|
Aug 07, 2026 | BUY |
Strong Buy
+127.7% avg upside
16 analysts
|
$15.00
32.69% Upside
|
+12.9% | Β· |
|
CGON
CG Oncology, Inc.
|
Aug 07, 2026 | BUY |
Strong Buy
+33.1% avg upside
17 analysts
|
$88.00
36.12% Upside
|
-0.9% | Β· |
|
JANX
Janux Therapeutics Inc
|
Aug 07, 2026 | BUY |
Strong Buy
+159.3% avg upside
22 analysts
|
$22.00
25.91% Upside
|
-28.3% | Β· |
|
AVTX
Avalo Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+561.5% avg upside
20 analysts
|
$35.00
388.10% Upside
|
-57.6% | Β· |
|
NTLA
Intellia Therapeutics
|
Aug 07, 2026 | HOLD |
Buy
+187.2% avg upside
39 analysts
|
$17.00
36.38% Upside
|
-18.8% | Β· |
|
EDIT
Editas Medicine
|
Aug 07, 2026 | SELL |
Buy
+398.5% avg upside
33 analysts
|
β | +24.6% | Β· |
|
TGTX
TG Therapeutics
|
Aug 05, 2026 | SELL |
Strong Buy
-30.0% avg upside
20 analysts
|
$21.00
65.70% Downside
|
-29.3% | Β· |
|
BTAIQ
Bioxcel Therapeutics
|
Mar 27, 2026 | SELL |
Strong Buy
+186224.8% avg upside
12 analysts
|
$1.00
7592.41% Upside
|
Β· | Β· |
|
REGN
Regeneron
|
Dec 10, 2024 | SELL |
Strong Buy
-12.1% avg upside
60 analysts
|
$565.00
39.03% Downside
|
+6.2% | Β· |
|
LLY
Eli Lilly & Co
|
Nov 01, 2024 | BUY |
Strong Buy
-16.7% avg upside
50 analysts
|
$1100.00
22.37% Downside
|
+6.2% | Β· |
|
DMRA
Damora Therapeutics
|
Aug 15, 2023 | BUY |
Strong Buy
+39.9% avg upside
20 analysts
|
$5.00
76.66% Downside
|
-16.5% | Β· |
|
NXTC
NextCure
|
Dec 02, 2022 | SELL |
Buy
+182.2% avg upside
10 analysts
|
$1.00
84.06% Downside
|
+14.9% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.